HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Lung Cancer

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2014.10.014PMID 25468202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.

  2014cited by this paper
• The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.

  2013cited by this paper
• Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

  2013influential reference
• The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

  2012influential reference
• Treatment of HER2-positive breast cancer: current status and future perspectives

  2012cited by this paper
• Characteristics of lung cancer in women: importance of hormonal and growth factors.

  2012cited by this paper
• Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

  2012influential reference
• Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis

  2012cited by this paper
• Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

  2012influential reference
• Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

  2011cited by this paper
• How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?

  2011cited by this paper
• Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.

  2011influential reference
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma

  2011cited by this paper
• Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

  2010influential reference
• The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data

  2010cited by this paper
• PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

  2010influential reference
• Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.

  2009cited by this paper
• HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

  2009cited by this paper
• Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

  2009cited by this paper
• HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

  2009cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non–Small Cell Lung Cancer

  2008cited by this paper
• Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.

  2007influential reference
• Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib

  2007cited by this paper
• Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.

  2006cited by this paper
• EGFR and erbB2 mutation status in Japanese lung cancer patients

  2006influential reference
• HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

  2006cited by this paper
• Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation

  2006influential reference
• Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features

  2006influential reference
• EGFR point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplification

  2006influential reference
• Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.

  2006influential reference
• Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

  2006cited by this paper
• ERBB2 kinase domain mutation in the lung squamous cell carcinoma.

  2006cited by this paper
• Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

  2005cited by this paper
• Somatic mutations of the protein kinase gene family in human lung cancer.

  2005influential reference
• Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

  2005influential reference
• Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

  2004cited by this paper
• Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers

  2004cited by this paper
• Athletics: Momentous sprint at the 2156 Olympics?

  2004influential reference
• HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.

  2003cited by this paper
• HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.

  2003cited by this paper
• Tumors of the lung

  1992cited by this paper
• Tumors of the Lung.

  1947cited by this paper

• Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies

  2025cites this paper
• Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study

  2025cites this paper
• Favourable Prognostic Significance of HER2 Mutations in Canine Pulmonary Adenocarcinoma Following Surgical Resection.

  2025cites this paper
• HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules

  2025influential citation
• Aberrations in the glycosylation of receptor tyrosine kinases: A focus on lung adenocarcinoma

  2025cites this paper
• Novel therapeutic strategies for rare mutations in non-small cell lung cancer

  2024cites this paper
• Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review

  2024cites this paper
• Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review

  2024cites this paper
• A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases

  2024influential citation
• EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation

  2024influential citation
• Exploring the correlation between HER2 alterations and 18F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients

  2023cites this paper
• HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies

  2023influential citation
• Küçük hücre dışı akciğer kanserlerinde immünhistokimyasal C-ERBB2 pozitivitesinin klinikopatolojik ve prognostik önemi

  2023cites this paper
• [Assessment of HER2 status of carcinomas of various localizations].

  2023cites this paper
• Clinicopathological significance of concurrent ErbB receptor expression in human meningioma

  2023cites this paper
• Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients

  2023cites this paper
• Feline Oncogenomics: What Do We Know about the Genetics of Cancer in Domestic Cats?

  2022cites this paper
• Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer.

  2022cites this paper
• Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era

  2022cites this paper
• HER2 Overexpression and Amplification in Feline Pulmonary Carcinoma

  2021influential citation
• Copy number gains of chromosome 17 identified by dual in situ hybridization in non-small cell lung cancer tissue correlate with overexpression of c-Myc

  2021cites this paper
• Immunohistochemical and Molecular Evaluation of Oncoprotein HER-2 in Women's Breast Cancer in The Republic of Congo

  2021cites this paper
• HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy

  2021cites this paper
• Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling

  2021cites this paper
• HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization

  2021cites this paper
• The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.

  2021cites this paper
• Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma

  2021influential citation
• Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.

  2021cites this paper
• Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

  2021cites this paper
• Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report

  2021cites this paper
• Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer

  2021cites this paper
• Advanced lung adenocarcinoma with coexistent HER2 mutation and amplification and response to afatinib: a case report.

  2020cites this paper
• Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

  2020cites this paper
• Clinical signifi cance of molecular-genetic markers in the diagnosis and personalization of lung cancer therapy

  2020influential citation
• Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review.

  2020cites this paper
• HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib

  2020cites this paper
• Catalog of Lung Cancer Gene Mutations Among Chinese Patients

  2020influential citation
• HER2 Mutated and Nonmutated Non-small Cell Lung Carcinomas Can Harbor Heterogeneous HER2 Gene Amplification and HER2 Protein Expression.

  2020cites this paper
• Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma

  2019cites this paper
• A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

  2019cites this paper
• HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.

  2019cites this paper
• Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea

  2019cites this paper
• Targeting HER2 in Lung Cancer

  2019cites this paper
• Application of Multiplex Ligation-Dependent Probe Amplification in Determining the Copy Number Alterations of HER Gene Family Members in Invasive Ductal Breast Carcinoma.

  2019cites this paper
• More efficient use of HER targeting agents in cancer therapy

  2019cites this paper
• Targeted Therapies for Lung Cancer

  2019cites this paper
• Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer

  2018cites this paper
• Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2

  2018influential citation
• Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

  2018cites this paper
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  2018cites this paper
• Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.

  2018cites this paper
• Endobronchial ultrasound – one year of experience in clinical practice

  2017cites this paper
• Current Trial Report Trastuzumab Emtansine in HER2þ Recurrent Metastatic NoneSmall-Cell Lung Cancer: Study Protocol

  2017cites this paper
• Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small‐Cell Lung Cancer: Study Protocol

  2017cites this paper
• HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.

  2017cites this paper
• The frequency and clinical impact of HER2 alterations in lung adenocarcinoma

  2017cites this paper
• Activating HER2 mutations as emerging targets in multiple solid cancers

  2017cites this paper
• Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method

  2017cites this paper
• Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases

  2017cites this paper
• Comparable clinical outcomes in patients with HER2‐mutant and EGFR‐mutant lung adenocarcinomas

  2017cites this paper
• Smoking, hormonal factors and molecular markers in female lung cancer.

  2016cites this paper
• Orientación cultural hacia la innovación en empresas. Un enfoque sociológico del Sistema de Innovación de Galicia

  2016cites this paper
• Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China

  2016influential citation
• HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

  2016influential citation
• Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics

  2016cites this paper
• Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens.

  2016cites this paper
• Mucinous micropapillary pattern in lung adenocarcinomas: a unique histology with genetic correlates

  2016cites this paper
• The many facets of lung adenocarcinoma – a disease comprising distinct molecular subgroups.

  2015cites this paper
• Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer

  2015cites this paper
• Clinicopathological and Survival Analysis of Japanese Patients with Resected Non–Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification

  2015cites this paper
• HER2異常等の低頻度の分子異常を有する非小細胞肺癌の臨床病理学的特徴を明らかにするための前向き観察研究（HER2-CS Study）と標準化学療法後再発・増悪または標準化学療法不応性のHER2陽性非小細胞肺癌患者を対象としたトラスツズマブエムタンシン（遺伝子組換え）の第2相試験

  2015cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1141 Prognosis , Prediction and Risk Assessment in the Prevention and Treatment of Non-Small Cell Lung Cancer

  2015cites this paper
• Prognosis, Prediction and Risk Assessment in the Prevention and Treatment of Non-Small Cell Lung Cancer

  2015cites this paper
• Analysis of different HER‐2 mutations in breast cancer progression and drug resistance

  2015cites this paper